The aforementioned inhibitors targeting downstream effectors of Rho GTPase signaling, such as fasudil, suppress amyloid metabolism and tauopathy in AD and FTD, and they also break down TDP-43, which aggregates in some forms of FTD and most kinds of ALS. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.